Prostate Cancer Clinical Trial
Official title:
Phase III Study of Chemo-hormonal Therapy Versus Hormonal Therapy Alone in Advanced Hormone-naives Prostate Cancer Patients.
Verified date | November 2008 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation
therapy may lessen the amount of androgens made by the body. Drugs used in chemotherapy,
such as docetaxel, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. It is not yet known whether giving
androgen ablation therapy together with docetaxel is more effective than giving androgen
ablation therapy alone in treating patients with advanced prostate cancer.
PURPOSE: This randomized phase III trial is studying androgen ablation and docetaxel to see
how well they work compared with androgen ablation alone in treating patients with advanced
prostate cancer.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the prostate - Meets one of the following criteria - Metastatic disease - Systemic progressive disease after locoregional therapy (surgery or radiotherapy) - No metastatic disease AND meets one of the following criteria: - Circulating PSA levels = 50 ng/mL (confirmed by = 2 subsequent evaluations) - Biochemical progression with a PSA doubling time < 6 months (with = 3 measurements taken 1 month apart) after primary locoregional treatment (radical prostatectomy or radiotherapy) with curative intent - Prostate-confined tumor with high-risk features whose therapy of choice is androgen deprivation - No symptomatic brain metastases or leptomeningeal disease PATIENT CHARACTERISTICS: - ECOG or Zubrod performance status 0-2 - Life expectancy = 6 months - ANC = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Hemoglobin = 10 g/dL - Bilirubin = 2.0 mg/dL - AST/ALT = 1.5 times upper limit of normal - Creatinine = 1.5 mg/dL - No active infection requiring IV antibiotics - No active ulcer, unstable diabetes mellitus, or other contraindication to corticotherapy - None of the following cardiovascular conditions: - Uncompensated heart failure (ejection fraction < 40%) - Myocardial infarction or revascularization procedure within the past 6 months - Unstable angina pectoris - Uncontrolled cardiac arrhythmia - No other severe clinical condition that, in the judgment of the local investigator, would place the patient at undue risk or interfere with the study - Not a prisoner - No prior malignancy, except for non-melanoma skin cancer, in situ cervical carcinoma, or other cancer that was curatively treated with no evidence of disease for = 5 years - No familial, social, or geographical condition or significant neurologic or psychiatric disorder that would preclude understanding or rendering informed consent or fully complying with study treatment and follow-up PRIOR CONCURRENT THERAPY: - At least 5 years since prior radiotherapy outside the prostate - Prior hormonal therapy allowed provided it was administered for = 6 months - At least 12 months since prior hormonal therapy - More than 30 days since prior participation in another clinical trial involving investigational agents - No prior surgical castration - Concurrent androgen deprivation for prostate cancer allowed provided it was started = 3 months prior to initiation of study treatment - Concurrent anticoagulant treatment allowed - No other concurrent investigational drugs |
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | Rete Oncologica Piemontese - Azienda Sanitaria Ospedale San Giovanni Battista Molinette di Torino | Turin |
Lead Sponsor | Collaborator |
---|---|
A.O.U. San Giovanni Battista di Torino, Italy |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 2-year progression-free survival rate | No | ||
Secondary | Overall survival | No | ||
Secondary | Time to treatment failure | No | ||
Secondary | Toxicity as assessed by NCI CTCAE criteria | Yes | ||
Secondary | PSA response rate (> 50% reduction from baseline) | No | ||
Secondary | Disease response rate as assessed by RECIST criteria (in patients with measurable disease) | No | ||
Secondary | PSA normalization (normal range 0-4 ng/mL) | No | ||
Secondary | Quality of life | No | ||
Secondary | Efficacy of treatment in controlling bone pain | No | ||
Secondary | Changes in chromogranin A levels | No | ||
Secondary | Cost analysis | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |